The FDA has issued a safety announcement warning the DPP-4 inhibitors or gliptins may cause joint pain that can be "severe and disabling".
A review of adverse events reported to the FDA and also medical literature identified cases of severe joint pain associated with the use of DPP-4 inhibitors. The pain may begin soon after starting treatment or after several years.
Patients are advised to report severe and persistent joint pain to a healthcare professional. If appropriate the healthcare professional should consider stopping treatment; symptoms usually improve within a month.
Action: Clinicians should be aware of this apparent side effect and take appropriate action when it is encountered.
|« Drug Safety Update - September 2015||NICE Guidance - September 2015 »|